PLIVA launches risperidone, paroxetine and torasemide
PLIVA d.d. ("PLIVA") is pleased to announce that it has launched a generic version of risperidone in Poland, under the trademark Risset. Risperidone is a drug for the treatment of psychotic disorders and symptoms such as hallucination, delusions and hostility. PLIVA's Risset is sold at a more affordable price than the original drug, benefiting both patients and state budget. The recently introduced legislation on therapeutic substitution has resulted in a positive early off-take of the product. According to IMS data for 2002, sales of risperidone reached US$ 23.1 m in Poland.
Zagreb, 11 July 2003
- PR_Risset_F.pdf (102,2 KB)
With 90 years of successful pharmaceutical experience, PLIVA is today a member of the Teva Group, one of the largest pharmaceutical companies in the world. We at PLIVA are dedicated to providing our customers with high quality, affordable medicines for a better quality of life.
As a responsible corporate citizen, PLIVA makes considerable investments in the communities in which it operates via its charitable donations program and public health actions, which directly contribute to healthcare improvement.